Development of Passive Immunotherapies for Synucleinopathies

Movement Disorders

Volumn 31, Issue 2, 2016, Pages 203-213

  Bergström, Ann Louise ^a   Kallunki, Pekka ^a   Fog, Karina ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Alpha synuclein; mechanism of action; Parkinson's disease, synucleinopathies; passive immunization

Indexed keywords

ALPHA SYNUCLEIN; MONOCLONAL ANTIBODY;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; CELL ACTIVATION; DEGENERATIVE DISEASE; HUMAN; IMMUNOTHERAPY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TARGETING; REVIEW; SYNUCLEINOPATHY; ANIMAL; CHEMISTRY; DISEASE MODEL; IMMUNOLOGY; LEWY BODY DISEASE; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; PROCEDURES;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; IMMUNIZATION, PASSIVE; LEWY BODY DISEASE; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE;

EID: 84952700538     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26481     Document Type: Review

References (72)

1. Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: clinical and pathological implications. Arch Neurol 2001;2:186–190.
2. Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 1998;16:9443–9449.
3. McLean PJ, Kawamata H, Ribich S, Hyman BT. Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J Biol Chem 2000;12:8812–8816.
4. Ueda K, Fukushima H, Masliah E, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 1993;23:11282–11286.
5. Kim TD, Paik SR, Yang CH. Structural and functional implications of C-terminal regions of alpha-synuclein. Biochemistry 2002;46:13782–13790.
6. Barbour R, Kling K, Anderson JP, et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 2008;2:55–59.
7. Bendor JT, Logan TP, Edwards RH. The function of alpha-synuclein. Neuron 2013;6:1044–1066.
8. Vargas KJ, Makani S, Davis T, Westphal CH, Castillo PE, Chandra SS. Synucleins regulate the kinetics of synaptic vesicle endocytosis. J Neurosci 2014;28:9364–9376.
9. Wu KP, Weinstock DS, Narayanan C, Levy RM, Baum J. Structural reorganization of alpha-synuclein at low pH observed by NMR and REMD simulations. J Mol Biol 2009;4:784–796.
10. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 1999;28:19509–19512.
11. Houlden H, Singleton AB. The genetics and neuropathology of Parkinson's disease. Acta Neuropathol 2012;3:325–338.
12. Lazaro DF, Rodrigues EF, Langohr R, et al. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. PLoS Genet 2014;11:e1004741.
13. Kim WS, Kagedal K, Halliday GM. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther 2014;5:73.
14. Beyer K, Lao JI, Carrato C, et al. Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies. Neuropathol Appl Neurobiol 2004;6:601–607.
15. Kuzdas-Wood D, Stefanova N, Jellinger KA, et al. Towards translational therapies for multiple system atrophy. Prog Neurobiol 2014;118:19–35.
16. Braak H, Del TK, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;2:197–211.
17. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008;5:501–503.
18. Li JY, Englund E, Widner H, et al. Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov Disord 2010;8:1091–1096.
19. Chu Y, Kordower JH. Lewy body pathology in fetal grafts. Ann N Y Acad Sci 2010;1184:55–67.
20. Hansen C, Angot E, Bergstrom AL, et al. alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011;2:715–725.
21. Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011;1:57–71.
22. Bellucci A, Navarria L, Zaltieri M, Missale C, Spano P. α-Synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. Brain Res 2012'1432:95–113.
23. Bellucci A, Zaltieri M, Navarria L, Grigoletto J, Missale C, Spano P. From alpha-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease. Brain Res 2012;1476:183–202.
24. Bousset L, Pieri L, Ruiz-Arlandis G, et al. Structural and functional characterization of two alpha-synuclein strains. Nat Commun 2013;4:2575.
25. Pacheco CR, Morales CN, Ramirez AE, et al. Extracellular alpha-synuclein alters synaptic transmission in brain neurons by perforating the neuronal plasma membrane. J Neurochem 2015;6:731–741.
26. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 2000;2:571–576.
27. Volles MJ, Lansbury PT Jr. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 2003;26:7871–7878.
28. Sato H, Kato T, Arawaka S. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models. Rev Neurosci 2013;2:115–123.
29. Oueslati A, Fournier M, Lashuel HA. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog Brain Res 2010;183:115–145.
30. Takahashi M, Suzuki M, Fukuoka M, et al. Normalization of overexpressed α-synuclein causing Parkinson's disease by a moderate gene silencing with RNA Interference. Mol Ther Nucleic Acids 2015;4:e241.
31. Frydman-Marom A, Shaltiel-Karyo R, Moshe S, Gazit E. The generic amyloid formation inhibition effect of a designed small aromatic beta-breaking peptide. Amyloid 2011;3:119–127.
32. Vekrellis K, Stefanis L. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies. Expert Opin Ther Targets 2012;4:421–432.
33. He Q, Koprich JB, Wang Y, et al. Treatment with trehalose prevents behavioral and neurochemical deficits produced in an AAV alpha-synuclein rat model of parkinson's disease. Mol Neurobiol 2015 [Epub ahead of print].
34. Schneeberger A, Tierney L, Mandler M. Active immunization therapies. Mov Disord 2015;doi: 10.1002/mds.26377
35. Masliah E, Rockenstein E, Mante M, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 2011;4:e19338.
36. Games D, Valera E, Spencer B, et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J Neurosci 2014;28:9441–9454.
37. Bae EJ, Lee HJ, Rockenstein E, et al. Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 2012;39:13454–13469.
38. Lindstrom V, Fagerqvist T, Nordstrom E, et al. Immunotherapy targeting alpha-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] alpha-synuclein mice. Neurobiol Dis 2014;69:134–143.
39. Shahaduzzaman M, Nash K, Hudson C, et al. Anti-human alpha-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-alpha-synuclein rat model of Parkinson's disease. PLoS.One 2015;2:e0116841.
40. Tran HT, Chung CH, Iba M, et al. Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration. Cell Rep 2014;6:2054–2065.
41. Masliah E, Rockenstein E, Adame A, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005;6:857–868.
42. Mandler M, Valera E, Rockenstein E, et al. Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener 2015;10:10.
43. Mandler M, Valera E, Rockenstein E, et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Acta Neuropathol 2014;6:861–879.
44. Lorenzen N, Lemminger L, Pedersen JN, Nielsen SB, Otzen DE. The N-terminus of alpha-synuclein is essential for both monomeric and oligomeric interactions with membranes. FEBS Lett 2014;3:497–502.
45. Sanchez-Guajardo V, Tentillier N, Romero-Ramos M. The relation between alpha-synuclein and microglia in Parkinson's disease: Recent developments. Neuroscience 2015;27:47–58.
46. Nasstrom T, Goncalves S, Sahlin C, et al. Antibodies against alpha-synuclein reduce oligomerization in living cells. PLoS.One. 2011;10:e27230.
47. Mishizen-Eberz AJ, Guttmann RP, Giasson BI, et al. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J Neurochem 2003;4:836–847.
48. Mishizen-Eberz AJ, Norris EH, Giasson BI, et al. Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry 2005;21:7818–7829.
49. Dufty BM, Warner LR, Hou ST, et al. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am J Pathol 2007;5:1725–1738.
50. Ritchie C, Thomas PJ. Alpha-synuclein truncation and disease. Health 2012;Special Issue:1167–1177.
51. Kellie JF, Higgs RE, Ryder JW, et al. Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson's disease brain tissue by intact protein mass spectrometry. Sci Rep 2014;4:5797.
52. Hall K, Yang S, Sauchanka O, Spillantini MG, Anichtchik O. Behavioural deficits in transgenic mice expressing human truncated (1-120 amino acid) alpha-synuclein. Exp Neurol 2015;264:8–13.
53. Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur J Neurosci 2010;3:409–422.
54. Nuber S, Harmuth F, Kohl Z, et al. A progressive dopaminergic phenotype associated with neurotoxic conversion of alpha-synuclein in BAC-transgenic rats. Brain 2013;136(Pt 2):412–432.
55. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 2002;12:2223–2226.
56. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007;1-2:54–61.
57. Smith AJ. New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics. J Biomol Screen 2015;4:437–453.
58. Malek N, Swallow D, Grosset KA, Anichtchik O, Spillantini M, Grosset DG. Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review. Acta Neurol Scand 2014;2:59–72.
59. Rodriguez-Araujo G, Nakagami H, Takami Y, et al. Low alpha-synuclein levels in the blood are associated with insulin resistance. Sci Rep 2015;5:12081.
60. Kang JH, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013;10:1277–1287.
61. Kruse N, Persson S, Alcolea D, et al. Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiol Aging 2015;36:2587–2596.
62. Petit GH, Berkovich E, Hickery M, et al. Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease. PLoS One 2013;4:e60691.
63. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002;4:521–533.
64. Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW. Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J Clin Neurol 2011;4:215–222.
65. Hansson O, Hall S, Ohrfelt A, et al. Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res Ther 2014;3:25.
66. Roberts RF, Wade-Martins R, Alegre-Abarrategui J. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain. Brain 2015;138(Pt 6) :1642–1657.
67. Fujiwara H, Hasegawa M, Dohmae N, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002;2:160–164.
68. Hasegawa M, Fujiwara H, Nonaka T, et al. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem 2002;50:49071–49076.
69. Anderson JP, Walker DE, Goldstein JM, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006;40:29739–29752.
70. Peelaerts W, Bousset L, Van der Perren A, et al. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 2015;522:340–344.
71. Vaikath NN, Majbour NK, Paleologou KE, et al. Generation and characterization of novel conformation-specific monoclonal antibodies for alpha-synuclein pathology. Neurobiol Dis 2015;79:81–99.
72. Spencer B, Emadi S, Desplats P, et al. ESCRT-mediated uptake and degradation of brain-targeted alpha-synuclein single chain antibody attenuates neuronal degeneration in vivo. Mol Ther 2014;10:1753–1767.